2021-22流感季美国18岁以下因流感住院或死亡儿童和青少年中SARS-CoV-2与流感共感染的患病率及临床特征
分析美国三个CDC监测平台2021-22流感季数据,18岁以下因流感住院或死亡者中SARS-CoV-2共感染率分别为6%(32/575)和16%(7/44)。共感染住院患者接受有创机械通气(4% vs 13%,p=0.03)和无创通气(6% vs 16%,p=0.05)的比例更高。7例共感染死亡者均未完成流感疫苗接种,仅1例接受流感抗病毒治疗。
要点
- 因流感住院儿童中SARS-CoV-2共感染率为6%(32/575),因流感死亡儿童中为16%(7/44)。
- 共感染住院患者有创机械通气比例13% vs 无共感染4%(p=0.03),无创通气16% vs 6%(p=0.05)。
- 7例共感染死亡者中无一完成流感疫苗接种,仅1例接受流感抗病毒治疗。
核心结论
- SARS-CoV-2共感染在因流感住院或死亡的儿童中均有发生,共感染住院患者接受有创机械通气和無创通气的比例高于无共感染者。
- 作者建议临床医生遵循推荐的呼吸道病毒检测算法指导治疗决策,并考虑对疑似或确诊流感患儿(包括住院或重症高风险SARS-CoV-2共感染者)早期启动抗病毒治疗。
- 作者建议公众和家长采取预防策略,包括在呼吸道病毒高流行时考虑佩戴贴合良好的高质量口罩,并保持≥6月龄人群的流感疫苗和COVID-19疫苗接种更新。
研究设计与样本
- 分析美国三个CDC监测平台数据:两个呼吸道病毒住院监测网络(RESP-NET)平台(2021年10月1日至2022年4月30日)和法定报告儿童流感相关死亡(2021年10月3日至2022年10月1日)。
- 研究对象为18岁以下因流感住院或死亡且报告至监测系统的患者。
主要发现
- 因流感住院的儿童中SARS-CoV-2共感染率为6%(32/575)。
- 因流感死亡的儿童中SARS-CoV-2共感染率为16%(7/44)。
- 共感染住院患者接受有创机械通气比例为13%,无共感染住院患者为4%(p=0.03)。
- 共感染住院患者接受双水平正压通气或持续正压通气(BiPAP/CPAP)比例为16%,无共感染住院患者为6%(p=0.05)。
- 7例共感染死亡患者中,无一完成流感疫苗接种,仅1例接受流感抗病毒治疗。
临床怎么用
- 作者建议临床医生遵循推荐的呼吸道病毒检测算法以指导治疗决策。
- 作者建议考虑对疑似或确诊流感的儿科患者早期启动抗病毒治疗,包括住院或重症高风险且SARS-CoV-2共感染者。
- 作者建议公众和家长在呼吸道病毒高流行时考虑佩戴贴合良好的高质量口罩。
- 作者建议保持≥6月龄人群的流感疫苗和COVID-19疫苗接种更新。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 2022-23 influenza season shows an early rise in pediatric influenza-associated hospitalizations (1). SARS-CoV-2 viruses also continue to circulate (2). The current influenza season is the first with substantial co-circulation of influenza viruses and SARS-CoV-2 (3). Although both seasonal influenza viruses and SARS-CoV-2 can contribute to substantial pediatric morbidity (3-5), whether coinfection increases disease severity compared with that associated with infection with one virus alone is unknown. This report describes characteristics and prevalence of laboratory-confirmed influenza virus and SARS-CoV-2 coinfections among patients aged <18 years who had been hospitalized or died with influenza as reported to three CDC surveillance platforms during the 2021-22 influenza season. Data from two Respiratory Virus Hospitalizations Surveillance Network (RESP-NET) platforms (October 1, 2021-April 30, 2022),§ and notifiable pediatric deaths associated¶ with influenza virus and SARS-CoV-2 coinfection (October 3, 2021-October 1, 2022)** were analyzed. SARS-CoV-2 coinfections occurred in 6% (32 of 575) of pediatric influenza-associated hospitalizations and in 16% (seven of 44) of pediatric influenza-associated deaths. Compared with patients without coinfection, a higher proportion of those hospitalized with coinfection received invasive mechanical ventilation (4% versus 13%; p = 0.03) and bilevel positive airway pressure or continuous positive airway pressure (BiPAP/CPAP) (6% versus 16%; p = 0.05). Among seven coinfected patients who died, none had completed influenza vaccination, and only one received influenza antivirals.†† To help prevent severe outcomes, clinicians should follow recommended respiratory virus testing algorithms to guide treatment decisions and consider early antiviral treatment initiation for pediatric patients with suspected or confirmed influenza, including those with SARS-CoV-2 coinfection who are hospitalized or at increased risk for severe illness. The public and parents should adopt prevention strategies including considering wearing well-fitted, high-quality masks when respiratory virus circulation is high and staying up-to-date with recommended influenza and COVID-19 vaccinations for persons aged ≥6 months.
引用
- Adams K, Tastad KJ, Huang S, et al. Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics Among Children and Adolescents Aged <18 Years Who Were Hospitalized or Died with Influenza - United States, 2021-22 Influenza Season. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36520656. doi:10.15585/mmwr.mm7150a4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。